All News
Filter News
Found 100 articles
-
Neoleukin Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
5/27/2020
Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:00 p.m. Eastern Time.
-
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Virtual Annual Meeting II
5/15/2020
-Preclinical Data on Lead Immunotherapy Candidate NL-201 Including Immunogencity Results in Non-Human Primates- -Novel Conditional Activation Platform Enabled by De Novo Protein Technology- -Preclinical Results Demonstrate Ability of NL-201 to Expand and Enhance CAR‑T Cell Activity- SEATTLE, May 15, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein thera
-
Neoleukin Therapeutics to Present at Virtual BofA Securities 2020 Health Care Conference
5/7/2020
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the virtual BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 2:20 p.m. Eastern Time. A live audio webcast of the session will be available from the investors section of th
-
Neoleukin Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update
5/6/2020
Neoleukin Therapeutics, Inc., a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced financial results for the first quarter ending March 31, 2020 and provided a business update.
-
Neoleukin Therapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held May 5, 2020
4/16/2020
Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced today that, due to the public health impact of the coronavirus disease 2019 (COVID-19) pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual meeting format only. As previously announced, the annual mee
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
-
Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities
4/9/2020
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today provided an update on the impacts of COVID-19 on the company’s corporate and research operations. “During this unprecedented time, protecting the health and well-being of our employees and community is a top priority. In addition, we are focused on maintaining continuity
-
Neoleukin Therapeutics Announces Year End Financial Results
3/12/2020
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the year ending December 31, 2019.
-
Neoleukin Therapeutics to Host 2019 Financial Results Conference Call and Webcast on March 12, 2020
3/5/2020
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2019 financial results on Thursday, March 12, 2020 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update
-
Neoleukin Therapeutics Announces Appointment of Robert K. Ho as Chief Financial Officer
2/25/2020
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Robert Ho as Chief Financial Officer, effective March 16, 2020.
-
Neoleukin Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
2/24/2020
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, 2020 at 3:30 p.m. Eastern.
-
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day
2/6/2020
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum | Oncology Day in New York City on Thursday, February 13, 2020 at 10 a.m. Eastern.
-
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/20/2019
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the closing of its public offering of 10,263,750 shares of its common stock at a public offering price of $8.40 per share,
-
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
12/18/2019
Neoleukin Therapeutics, Inc. announced the pricing of an underwritten public offering of 8,925,000 shares of its common stock at a price to the public of $8.40 per share.
-
Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
12/17/2019
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to $50.0 million of shares of its common stock in an underwritten public offering.
-
Neoleukin Therapeutics Announces Scientific Advisory Board Preeminent leaders in protein design, structural biology and immunology
12/5/2019
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the formation of a Scientific Advisory Board comprised of leaders in the fields of de novo protein design, structural biology and immunology.
-
Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
11/26/2019
Neoleukin Therapeutics, Inc. “Neoleukin” announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5, 2019 at 2:50 p.m. EST in New York.
-
Neoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results
11/13/2019
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the third quarter ending September 30, 2019.
-
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
-
Seattle-based Neoleukin Therapeutics spun out of the University of Washington Medicine’s Institute for Protein Design's research with the help of CoMotion, a collaborative innovation hub.